Has Henry Igid, MD received payments from drug or device companies?

Yes. Drug and device makers reported $79,697 in general payments to Henry Igid, MD across 771 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Henry Igid, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Henry Igid, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Henry Igid, MD

Hematology & Oncology · Las Vegas, NVNPI 1003182106

Payments from drug & device makers

$79,697in general payments, 2019–2025

Across 771 payments — averaging $103.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Seagen Inc.$23K
Karyopharm Therapeutics Inc.$16K
Morphosys AG$12K
Pfizer$6K
AstraZeneca$5K
Lilly USA, LLC$1K
plus $16K from 54 others

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Seagen Inc.	37	$22,839
Karyopharm Therapeutics Inc.	15	$16,371
Morphosys AG	5	$11,899
Pfizer	43	$6,048
AstraZeneca(2 entities)	57	$4,796
Lilly USA, LLC	13	$1,488
Johnson & Johnson(2 entities)	49	$1,488
Daiichi Sankyo Inc.	79	$1,359
Amgen	34	$1,015
Novartis	44	$858
AbbVie	20	$690
Incyte Corporation	15	$663
Astellas Pharma US Inc	19	$621
Genentech USA, Inc.	26	$600
Bayer	18	$454
Bristol Myers Squibb	17	$453
Gilead	7	$422
Sanofi	17	$409
Sobi, Inc	22	$338
Blueprint Medicines Corporation	8	$338
Tempus AI, Inc	20	$314
Beigene USA, Inc.	6	$310
Jazz Pharmaceuticals Inc.	5	$307
Stemline Therapeutics Inc.	9	$302
Merck	13	$277
EMD Serono, Inc.	11	$265
GSK	10	$264
E.r. Squibb & Sons, L.L.C.	8	$252
Eisai Inc.	7	$237
Secura Bio, Inc.	1	$230
Rigel Pharmaceuticals, Inc.	5	$224
ADC Therapeutics America, Inc.	4	$213
Exelixis Inc.	7	$211
Pharmacyclics LLC, An Abbvie Company	9	$192
Medtronic	1	$160
Pharmacosmos Therapeutics Inc.	1	$144
Pharmaessentia USA Corporation	2	$141
Ipsen Biopharmaceuticals, Inc	5	$131
Genentech, Inc.	4	$128
Regeneron Healthcare Solutions, Inc.	6	$119
Boehringer Ingelheim	4	$112
Takeda Pharmaceuticals U.S.A., Inc.	4	$107
Sumitomo Pharma America, Inc.	5	$102
Agios Pharmaceuticals, Inc.	4	$101
Dendreon Pharmaceuticals LLC	3	$94
Array Biopharma Inc	6	$93
AMAG Pharmaceuticals, Inc.	4	$88
Global Blood Therapeutics, Inc.	4	$83
Mirati Therapeutics, Inc.	4	$82
AVEO Pharmaceuticals, Inc.	3	$81
Genmab U.S., Inc.	3	$77
Janssen Scientific Affairs, LLC	3	$74
Sanofi-aventis U.S. LLC	1	$65
Clovis Oncology, Inc.	4	$61
Dova Pharmaceuticals	3	$56
Blue Earth Diagnostics	1	$56
Novocure Inc.	2	$56
Heron Therapeutics, Inc.	3	$50
Kyowa Kirin, Inc.	2	$42
Alnylam Pharmaceuticals Inc.	2	$42

How this compares

$79,697 in reported general payments places this provider in the 60th percentile of 82 hematology & oncology providers in Nevada.

See all hematology & oncology providers in Nevada →

Medicare billing

Part B allowed, 2024

$5,088,213

Medicare patients

706

Services billed

268,307

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other hematology & oncology in Las Vegas

Edwin KingsleyLas Vegas$9.2M
Nicholas VogelzangLas Vegas$8.3M
Oscar GoodmanLas Vegas$6M
Khawaja JahangirLas Vegas$2.5M
Carolyn MulroneyLas Vegas$1.5M
Wolfram SamlowskiLas Vegas$1.1M
Anuradha ThummalaLas Vegas$736K
Grzegorz ObaraLas Vegas$668K
Aaron GoodmanLas Vegas$480K
Vikas GuptaLas Vegas$300K

See the full list for Nevada →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →